Xeltis Bioabsorbable Pulmonary Valved Conduit Pivotal Study (Xplore2)

• ClinicalTrials.gov Identifier: NCT03022708
• Recruitment Status: Enrolling by invitation
• First Posted: January 16, 2017
• Last Update Posted: January 26, 2023
• Sponsor: Xeltis
• Information provided by (Responsible Party): Xeltis

Study Description

Brief Summary:

This is a multi-center prospective, single-arm, non-randomized, pivotal study that will continue to access the feasibility of the Xeltis Bioabsorbable Pulmonary Valved Conduit in subjects requiring right ventricular outflow tract correction or reconstruction due to congenital heart malformations.

Condition or disease	Intervention/treatment	Phase
Heart Defect, Congenital	Device: Xeltis Bioabsorbable Pulmonary Valved Conduit	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 56 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Prospective, Non-randomized, Pivotal Study to Assess the Safety and Efficacy of the Bioabsorbable Pulmonary Valved Conduit in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction
• Actual Study Start Date: May 8, 2017
• Estimated Primary Completion Date: December 2023
• Estimated Study Completion Date: December 2026

Arms and Interventions

Arm

Intervention/treatment

Experimental: Xeltis Bioabsorbable Pulmonary Valved Conduit; The Bioabsorbable Pulmonary Valved Conduit bio-absorbable, polymer-based medical device. The PV conduit is used in patients for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT), in patients less than 22 years with any of the following congenital heart malformations: Tetralogy of Fallot; Truncus Arteriosus; Pulmonary Atresia; Transposition of Great Arteries with Ventricular Septal Defect; Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes In addition, the PV conduit can be used for the following indications: replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits (except for mechanical valves, see exclusion criterion 3).; Patients undergoing a Ross procedure, where the PV conduit would replace the patient's own pulmonary valve which is used to replace a diseased aortic valve.

Device: Xeltis Bioabsorbable Pulmonary Valved Conduit; Surgical implantation of Xeltis Bioabsorbable Pulmonary Valved Conduit

Outcome Measures

Primary Outcome Measures :

1. Composite rate of events of device related death, re-operation or re-intervention at 12 months follow-up. [ Time Frame: 12 months ]
   Measured once all 12 month follow up visits have been completed

Secondary Outcome Measures :

1. Overall rate of device related death due to device failure at 6 months follow up post implantation. [ Time Frame: 6 months ]
   Measured once all 6 month follow up visits have been completed
2. Overall rate of mortality at 60 months follow up post implantation. [ Time Frame: 60 months ]
   Measured once all 60 months follow up visits have been completed
3. Overall rate of subjects who require reoperation or re-intervention due to device failure 12 months. [ Time Frame: 12 months ]
   Measured once all 12 month follow upvisits have been completed .
4. Overall rate of subjects with a mean pressure gradient across the area of conduit implantation of less than 40 mm Hg at 6 and 12 months follow up. [ Time Frame: 6 and 12 months ]
   Measured by echography at 6 and 12 months follow up.
5. Overall rate of subjects with pulmonary regurgitation of equal or less than moderate at 6 and 12 months follow up. [ Time Frame: 6 and 12 months ]
   Measured by echography at 6 and 12 months follow up.

Other Outcome Measures:

1. Measurement of growth of conduit in pediatric population measured at 6, 36, 48 and 60 months. A competent valve with increased valve diameter in age groups < 18 years in correlation with the increased body surface area. [ Time Frame: Up to 60 months ]
   Measured with echocardiography at 6, 36, 48 and 60 months follow up.
2. Overall satisfaction of the implanting surgeon of the implantation procedure of the Bio-absorbable pulmonary valve conduit [ Time Frame: Day 0 - Implant ]
   Measured with a questionnaire given to the implanting surgeon at the time of implantation of the pulmonary valve conduit.

Eligibility Criteria

• Ages Eligible for Study: 2 Years to 21 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Patient requiring RVOT reconstruction, suitable for 16 mm,18 mm, 20 mm and 22 mm valved conduit.
2. Male or Female.
3. Age > 2 years and < 22 years.
4. Right Ventricular to Pulmonary Artery peak gradient > 35mm Hg or moderate or severe Pulmonary regurgitation (≥3+), or have both (except for the patients undergoing a Ross procedure)
5. The patient, and the patient's parent / legal representative where appropriate, has been informed of the nature of the study, agrees to its provisions and has provided written informed consent by signing the approved informed consent form.
6. The patient, and the patient's parent / legal representative where appropriate, and the treating physician agree that the subject will return for all required post-procedure follow up visits and the subject will comply with clinical investigation plan required follow-up visits.

Exclusion Criteria:

1. Need for or presence of prosthetic heart valve at other position.
2. Need for concomitant surgical procedures (non-cardiac).
3. Patients with previously implanted pacemaker (including defibrillators), or mechanical valves.
4. Active infection or requiring current antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics) or viral infection.
5. Active endocarditis.

6. Leukopenia, defined as White Blood cell Count < than:

   • 2-12 years: 5.0 ×103 /μL
   • 12 years - Adult:
   • Male: 4.5×103 /μL
   • Female: 4.5 ×103 /μL

7. Acute or chronic anemia, defined as Hemoglobin < than:

   • 2-12 years 11.5 g /dl
   • 12-18:
   • Male: 13 g /dl
   • Female 12 g /dl
   • Adult:
   • Male: 13.5 g /dl
   • Female: 12 g /dl Patients can be transfused to meet eligibility criteria

8. Thrombocytopenia, defined as Platelet count < than:

   • 150,000/mm3 Patients can be transfused to meet eligibility criteria
9. Severe chest wall deformity, which would preclude placement of the PV conduit.
10. Pulmonary hypertension (≥ half of systemic systolic pressure)
11. Right ventricular outflow tract aneurysm.
12. Known hypersensitivity to anticoagulants and antiplatelet drugs and to the device materials. .
13. Immunocompromised patient defined as: autoimmune disease, patients receiving immunosuppressant drugs or immune stimulant drugs.
14. Subject has chronic inflammatory / autoimmune disease.
15. Need for emergency cardiac or vascular surgery or intervention.
16. Major or progressive non-cardiac disease (liver failure, renal failure, cancer) that has a life expectancy of less than one year.
17. Currently participating, or participated within the last 30 days, in an investigational drug or device study.
18. Alcohol or drug abuse as defined by DSM IV-TR criteria for substance abuse - this includes the illicit use of cannabis within the last 12 months.
19. Pregnancy.
20. Females who are sexually active and are not willing to use adequate contraceptive precautions for the next 2 years
21. Subject has medical, social or psychosocial factors that, in the opinion of the Investigator, could impact safety or compliance.

Contacts and Locations

Locations

United States, California

Children's Hospital of Los Angeles

Los Angeles, California, United States, 90027

United States, Colorado

Children's Hospital Colorado

Aurora, Colorado, United States, 80045

United States, Florida

Joe DiMaggio Children's Hospital

Hollywood, Florida, United States, 33021

United States, New York

New York Presbyterian Hospital - Columbia University (Xplore1)

New York, New York, United States, 10032

United States, Ohio

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

United States, Pennsylvania

Children's Hospital of Pittsburgh of UPMC (Xplore1)

Pittsburgh, Pennsylvania, United States, 15224

United States, Texas

UTSW- Dallas Children's Hospital

Dallas, Texas, United States, 75390-8835

Bulgaria

Multiprofile Hospital for Active Treatment "National cardiology hospital" EAD, Department of Congenital Heart Defects Surgery

Sofia, Bulgaria

Malaysia

Institut Jantung Negara Sdn Bhd

Kuala Lumpur, Malaysia

Poland

University Children's Hospital of Cracow

Kraków, Poland

Sponsors and Collaborators

Xeltis

Investigators

• Study Director: Eliane Schutte; Xeltis Inc

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Morales DL, Herrington C, Bacha EA, Morell VO, Prodan Z, Mroczek T, Sivalingam S, Cox M, Bennink G, Asch FM. A Novel Restorative Pulmonary Valve Conduit: Early Outcomes of Two Clinical Trials. Front Cardiovasc Med. 2021 Mar 4;7:583360. doi: 10.3389/fcvm.2020.583360. eCollection 2020.

• Responsible Party: Xeltis
• ClinicalTrials.gov Identifier: NCT03022708
• Other Study ID Numbers: XEL-CR-03
• First Posted: January 16, 2017
• Last Update Posted: January 26, 2023
• Last Verified: January 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Device Product Not Approved or Cleared by U.S. FDA: Yes

Additional relevant MeSH terms:

Heart Defects, Congenital; Congenital Abnormalities; Cardiovascular Abnormalities; Cardiovascular Diseases; Heart Diseases